Two Salts and the Salt Co-Crystal of Ciprofloxacin with Thiobarbituric and Barbituric acids: the Structure and Properties

Nicolay N. Golovnev^a, Maxim S. Molokeev^{a,b,c*}, Maxim K. Lesnikov^a, Victor V. Atuchin^{d,e,f,g,h}

^a Siberian Federal University, 79 Svobodny Ave., Krasnoyarsk 660041, Russia

^b Laboratory of Crystal Physics, Kirensky Institute of Physics, Federal Research Center KSC SB

RAS, bld. 38 Akademgorodok 50, Krasnoyarsk 660036, Russia

^c Department of Physics, Far Eastern State Transport University, 47 Seryshev Str., Khabarovsk

680021, Russia

^d Laboratory of Optical Materials and Structures, Institute of Semiconductor Physics, SB RAS,

Novosibirsk 630090, Russia

^eFunctional Electronics Laboratory, Tomsk State University, Tomsk 634050, Russia

^f Laboratory of Semiconductor and Dielectric Materials, Novosibirsk State University,

Novosibirsk 630090, Russia

⁸ Institute of Chemistry, Tyumen State University, Tyumen 625003, Russia

^hLaboratory of Single Crystal Growth, South Ural State University, Chelyabinsk 454080,

Russia

* Corresponding author:

Maxim Molokeev

E-mail: msmolokeev@gmail.com

Laboratory of Crystal Physics, Kirensky Institute of Physics, SB RAS, bld. 38 Akademgorodok 50,

Krasnoyarsk 660036, Russia

Tel.: +7-391-249-45-07

†Electronic supplementary information (ESI) available. See DOI:xxx

Abstract

Ciprofloxacin (CfH, $C_{17}H_{18}FN_3O_3$) crystallizes with 2-thiobarbituric (H_2 tba) and barbituric acid (H_2 ba) in the aqueous solution to yield salt $CfH_2(Htba)\cdot 3H_2O$ (1), salt co-crystal $CfH_2(Hba)(H_2ba)\cdot 3H_2O$ (2) and salt $CfH_2(Hba)\cdot H_2O$ (3). The compounds are structurally characterized by the X-ray single-crystal diffraction. The numerous intermolecular hydrogen bonds N—H···O and O—H···O, forming of water molecules, $Htba^-/Hba^-$ and CfH_2^+ ions, and

1

H₂ba molecules stabilize the crystal structures of **1-3**. Hydrogen bonds form a 2D plane network in the salts of **1** and **3**, and a 3D network in the salt co-crystal of **2**. There are different π - π interactions in **1-3**. The compounds have been characterized by powder XRD, TG-DSC and FT-IR. The compounds dehydration ends at 130-150 °C, and their oxidative decomposition is observed in the range of 250-275 °C.

Keywords: Thiobarbituric acid; barbituric acid; ciprofloxacin; salts; salt co-crystal; X-ray diffraction; infrared spectroscopy; thermal stability

1. Introduction

Fluoroquinolones are one of the most important classes of synthetic antibiotics [1]. However, the molecular mechanism of this enzyme inhibition is still unknown [2, 3]. Ciprofloxacin (CfH), 1-Cyclopropyl-6-fluoro-4-oxo-7(piperazin-1-yl)-1,4-dihydro-3quinolinecarboxylic acid (Fig. 1a) is a widely prescribed broad-spectrum oral fluroquinolone antibiotic [4]. It forms different unstable hydrates [5]. In the aqueous solution, CfH exists predominantly as a zwitterion (isoelectric point = 7.42). Its intrinsic solubility in water at 25 °C is comparatively low ca. $0.08 \text{ g} \cdot 1^{-1}$ [6]. One obvious way to increase the aqueous solubility of CfH is to make a salt [7]. The most common marketed form of CfH is that of the hydrochloride monohydrate. Evidently, a further search for other ciprofloxacin salts with improved properties is of great practical interest in pharmacology [8, 9]. Along with the salts, it is possible to use the so-called salt co-crystals [10, 11] (or ionic co-crystals, ICCs [12]). The term "salt co-crystal" indicates that a salt, be it inorganic and organic, can co-crystallize with an organic molecule [11]. In a co-crystal, if at least one of coformers is a drug molecule or ion, then it is termed as a pharmaceutical co-crystal [13]. Today, the discovery and exploration of pharmaceutical cocrystals and salts present a major perspective for the controlled modification of key pharmaceutical properties, such as solubility, hydroscopicity, physicochemical stability, photostability and dissolution performance [14].

Barbituric (H_2ba) and thiobarbituric (H_2tba) acids (Fig. 1b) are the lead structures of 5,5-substituted barbiturates and thiobarbiturates, respectively, and they are important groups of sedative/hypnotic drugs [15]. The Hba^- and $Htba^-$ anions are exceptionally good hydrogen bonding acceptors and donors, which is important for the crystal design of pharmaceuticals and molecular recognition [16]. They can be linked by intermolecular hydrogen bonds to other complementary neutral molecules, for example, such as H_2ba and H_2tba , to form salt co-crystals [10, 17, 18]. Thus, salt co-crystals $M(Hba)(H_2ba)\cdot 2H_2O$ (M = Na, K), $K(Hba)(H_2ba)_{0.5}\cdot 1.5H_2O$

[10] and Rb(Hba)(H₂ba)·H₂O [17] were previously synthesized. The formation of co-crystals leads to an increase of the H₂ba thermal stability [10]. In the present work, for the first time [19], the structures of compounds formed by fluoroquinolones and barbituric/thiobarbituric acids were solved. The fundamental aim of the present work is to evaluate the solid-state of these compounds. The ciprofloxacinium thiobarbiturate trihydrate, CfH₂(Htba)·3H₂O (1), ciprofloxacinium 2-thiobarbiturate 2-thiobarbituric acid trihydrate, CfH₂(Hba)(H₂ba)·3H₂O (2) and ciprofloxacinium barbiturate monohydrate, CfH₂(Hba)·H₂O (3) are synthesized and structurally characterized by the X-ray single-crystal diffraction. Besides, the spectroscopic and thermal properties of 1-3 were observed.

2. Experimental section

2.1. Chemical reagents

Barbituric acid (CAS 67-52-7) and 2-thiobarbituric acid (CAS 504-17-6) were purchased from Sigma-Aldrich and used without further purification. Ciprofloxacinium chloride monohydrate (CfH·HCl·H₂O, Ranbaxia, India) was used without further purification.

2.2. Synthesis

0.2 g (0.5 mmol) of ciprofloxacin hydrochloride monohydrate was dissolved in 5 ml of water, then 0.074 g (0.5 mmol) H₂tba and 0.02 g (0.5 mmol) NaOH were added. The resulting mixture was heated to 80°C and held at this temperature for 30 min. The pale yellow bulk precipitate formed in the solution was filtered off and discarded as it consists of a mixture of several phases. The hot filtrate (pH 4) was cooled to room temperature and held at 3°C for two days. The formed pale yellow crystal precipitate of CfH₂(Htba)·3H₂O (1) was filtered, washed with water (1 ml), acetone and dried in the air (yield 30 %).

The synthesis of CfH₂(Hba)·H₂O (3) was performed similar to the synthesis of 1, except for an equimolar amount of H₂ba (0.064 g, 0.5 mmol) used instead of H₂tba. After dissolving all the reagents at 80°C, the solution was slowly cooled to room temperature (pH 4.6) and, then, the resulting colourless crystalline precipitate was filtered off, washed with water (1 ml), acetone and air-dried (yield 58%).

Compound $CfH_2(Hba)(H_2ba)\cdot 3H_2O$ (2) was obtained under similar conditions, except for that the double excess of H_2ba (0.128 g, 1.0 mmol) was used. After dissolving all the reagents at $80^{\circ}C$, the solution was slowly cooled to room temperature (pH 4.0) and then stored at $2^{\circ}C$ for 24 h. The resulting pale yellow crystalline precipitate was filtered off, washed with water (1 ml), acetone and air-dried (yield 60%).

The elemental analysis for $C_{21}H_{28}FN_5O_8S$ (1): Calc.: C, 47.6%; H, 5.33%; N, 13.2%; S, 6.06. Found: C, 47.2%; H, 5.52%; N, 12.9%; S, 6.21%. The elemental analysis for $C_{25}H_{32}FN_7O_{12}$ (2): Calc.: C, 46.8%; H, 5.03%; N, 15.3%. Found: C, 46.2%; H, 5.22%; N, 15.0%. The elemental analysis for $C_{21}H_{24}FN_5O_7$ (3): Calc.: C, 52.8%; H, 5.07%; N, 14.7%. Found: C, 52.2%; H, 5.24%; N, 14.5%.

The single crystals suitable for a structural analysis were selected directly from the total mass of precipitates **1-3**. The powder patterns of **1-3**, simulated from the single crystal structural data, well agree to the measured ones (Figs. 1S, 2S, 3S) indicating that the corresponding crystal structures represent the bulk structures.

2.2. X-ray diffraction analysis

The intensity patterns were collected from single crystals **1-3** using the SMART APEX II diffractometer (Bruker AXS) equipped with a CCD-detector, graphite monochromator and Mo-K α radiation source. The absorption corrections were applied using the SADABS program. The structures were solved by the direct methods using package SHELXS and refined in the anisotropic approach for non-hydrogen atoms using the SHELXL program [20]. All hydrogen atoms were found via Fourier difference maps. Further, the hydrogen atoms which are linked with C,N atoms in the Htba⁻ and CfH₂⁺ ions in **1** and **2** were positioned geometrically as riding on their parent atoms with d(C–H) = 0.93-0.98 Å, d(N–H)=0.86-0.89 Å depending on the geometry and U_{iso}(H) = 1.2U_{eq}(C,N). All hydrogen atoms of the H₂O molecules and one H atom in the OH group of CfH₂⁺ ion were refined with bond length restraint d(O–H)=0.9 Å and U_{iso}(H) = 1.2U_{eq}(O). The structure test for the presence of missing symmetry elements and possible voids was produced using program PLATON [21]. The DIAMOND program is used for the crystal structure plotting [22].

The powder X-ray diffraction data were obtained using diffractometer D8 ADVANCE (Bruker) equipped by a VANTEC detector with a Ni filter. The measurements were made using Cu K α radiation. The structural parameters defined by single crystal analysis were used as a base in the powder pattern Rietveld refinement.

2.3. Physical measurements

TGA was carried out on the simultaneous SDT-Q600 thermal analyzer (TA Instruments, USA) under the dynamic air atmosphere (50 ml/min flow rate) within 25–350 °C at the scan rate of 10 °C/min. The qualitative composition of the evolved gases was determined by FT-IR spectrometer Nicolet380 (Thermo Scientific, USA) combined with a thermal analyzer and with the TGA/FT-IR interface (attachment for the gas phase analysis). This set up allows making a

simultaneous accumulation of the DTA and TG data, and the composition of the released gas phase. The compound weight was 6.442 mg for **1**, 8.433 mg for **2** and 4.442 mg for **3**. Platinum crucibles with perforated lids were used as the containers. The IR absorption spectra of the compounds inserted into the KBr tablets were recorded over the range of 400–4000 cm⁻¹ at room temperature on an FT-IR spectrometer Nicolet 6700 (Thermo Scientific, USA, SFU CEJU).

3. Results and discussion

3.1. Crystal structures of 1

The unit cell of $CfH_2^+(Htba^-)\cdot 3H_2O$ corresponds to the triclinic symmetry. Space group P-1 was determined from the statistical analysis of the reflection intensities. The main crystal data are shown in Table 1. The corresponding bond lengths C—O, C—S, C—N, C—C and valence angles in the CfH₂⁺ cation and Htba⁻ anion (Table 1S) well related to those found earlier for other compounds [8, 9, 19, 23-31]. The independent part of the unit cell contains one CfH₂⁺ ion, one Htba⁻ ion and three H₂O molecules (Fig. 2a). There are two intramolecular hydrogen bonds C-H...F. O-H...O and ten intermolecular hydrogen bonds N-H...O and O-H...O in structure 1 (Fig. 3a, Table 2) which form the 2D plane network. This is a 5-nodal net with (3-c)(3-c)(3-c)(4-c)(5-c)and with the $(4.5^2.6^2.7)(4.5^4.6.7^3.8)(5.6.7)(5.6.9)(5^2.7)$, which is new [32]. Hydrogen bonds form two alternating infinite chains, one of them consists of CfH₂⁺ ions bound by water molecules; the second one consists of Htba⁻ ions and water molecules (Figure 3a). Each CfH₂⁺ ion in the chain forms H-bonds with two water molecules, while the sequence of molecules is CfH₂⁺···H₂O···CfH₂⁺···H₂O. When the CfH₂⁺ ion interacts with one water molecule H₂(O1W), the piperazin-1-yl N atom of NH₂⁺ group is the H-bond donor (N1—H···O1W), but when the CfH₂⁺ ion interacts with another water molecule H₂(O2W), the O2 atom is the H-bond acceptor (Hbond O2W—H···O2). Htba-ions are combined together by hydrogen bonds N—H···O into pairs with the formation of supramolecular motif $R_2^2(8)$, which is often found in other thiobarbiturate compounds [23-30]. These pairs are connected together by H-bonds with the participation of two water molecules (cyclic motif $R_4^2(8)$) and that results in the formation of an infinite chain. The interesting ring supramolecular motifs in this network are formed by the hydrogen bonds between ions CfH₂⁺ and Htba⁻ (R₅⁵(14), R₆⁵(27)) (Fig. 3a). Also, there are π - π interactions between Htba⁻ and CfH₂⁺ rings (Table 2S, Fig. 4Sa). CfH₂⁺ ions are connected in pairs by the π - π interaction of head-to-tail type.

3.2. Crystal structure of 2

Compound CfH₂(Hba)(H₂ba)·3H₂O (2) is a pharmaceutical co-crystal [13]. The unit cell of CfH₂(Hba)(H₂ba)·3H₂O (2) also corresponds to the triclinic symmetry. Space group P-1 was determined from the statistical analysis of the reflection intensities. The main crystal data can be found in Table 1. The main bond lengths C—O, C—N, C—C and valence angles are enumerated in Table 1S. They coincide with those given in the literature for the CfH₂⁺ [8, 9, 19] and uncoordinated Hba⁻ ions [33-36]. The main geometric parameters of H₂ba in 2 coincided with those found in the free keto form H₂ba [37] and co-crystals [10, 17]. The independent part of the unit cell contains one CfH₂⁺ ion, one Hba⁻ ion (A), one H₂ba (B) molecule and three H₂O molecules (Fig. 2b). There are two intramolecular hydrogen bonds C-H···F, O-H···O and twelve intermolecular hydrogen bonds N—H···O, O—H···O in the structure (Fig. 3b, Table 2) which form a 3D network. This is a 4-nodal net with stoichiometry (3-c)(3-c)(3-c)(5-c) and point symbol $(4.5.6)_2(5.6^2)(5^2.6^3.8.9^4)(6.10^2)$, which is also new [32]. Intermolecular hydrogen bonds N—H...O form the chain of alternating Hba⁻ and H₂ba in the keto form based on the $R_2^2(8)$ pattern. In compounds $Rb(Hba)(H_2ba)\cdot 3H_2O$ [17] and $M(Hba)(H_2ba)\cdot 3H_2O$ (M = Na, K) [10], the chains with sequence H₂ba···Hba⁻···H₂ba···Hba⁻.also are formed. However, in K(Hba)(H₂ba)_{0.5}·1.5H₂O, sequence H₂ba···Hba⁻···H₂ba is observed [10]. Salt co-crystals $MBr \cdot H_2ba$ (M = Rb, Cs) and $CsI \cdot H_2ba$ are characterized by the presence of H_2ba dimers linked via N—H···O hydrogen bonds [38]. Dimeric fragment H₂tba···Htba⁻ was observed in the salt cocrystal of piperidinium (PipeH⁺) 2-thiobarbiturate and 2-thiobarbituric acid, PipeH(Htba)H₂tba [18]. In 2, two water molecules joint CfH_2^+ ions in pairs by hydrogen bonds $O-H\cdots O$ forming a 16-membered ring ($R_6^4(16)$). Hydrogen bonds OW—H···OW' attract four water molecules (motif R₄⁴(8)) in the cycle, three of which are bound by hydrogen bonds OW—H···O3A with three Hba-(A) ions, forming two bound infinite chains "Hba" "H2ba" (Fig. 3b). CfH2⁺ ions are also combined into pairs by intermolecular hydrogen bonds OW-H...O with the participation of just two water molecules. Each CfH₂⁺ ion is bound to Hba⁻ or H₂ba by a single hydrogen bond N1—H···O (Table 2). The hydrogen bonds involving Hba⁻ ions, H₂ba and H₂O molecules also form other cyclic motifs in this network $R_4^4(8)$, $R_5^4(14)$ and $R_6^6(20)$ (Fig. 3b). There are π - π interactions between Hba⁻ and CfH₂⁺ rings in 2. Like in 1, two CfH₂⁺ form the pairs in 2 (Table 2S, Fig. 4Sb).

3.3. Crystal structure of (3) and comparison

The unit cell of CfH₂(Hba)·H₂O (3) corresponds to the monoclinic symmetry. Space group $P2_1/c$ was determined from the extinction rules and statistical analysis of the reflection intensities. The main crystal data are summarized in Table 1. The main defined bond lengths and valence angles are shown in Table 1S. They relate well to those found in 2 and in the literature

for the CfH₂⁺ [8, 9, 19] and Htba⁻ ions [33-36]. The independent part of the unit cell contains one CfH⁺ ion, one Hba⁻ ion and one H₂O molecule (Fig. 2c). There are two intramolecular hydrogen bonds C–H···F, O–H···O and five intermolecular hydrogen bonds N–H···O, O–H···O in the structure (Fig. 3c, Table 2), which form a 2D network.

Hba⁻ ions are connected to each other by two hydrogen bonds N—H···O, closing the 8-membered ring (R₂²(8)). As a result, they form their infinite chains along the *a*-axis. With the help of H-bonds N1—H···O and O—H···O, these infinite chains of Hba⁻ ions are joined together by other chains containing one ion CfH₂⁺, H₂O and Hba⁻. The H-bond donor is the positively charged piperazinium N1 atom in CfH₂⁺, which directly joints CfH₂⁺ and Hba⁻ using H-bond N1—H···O2A. The acceptor O3 atom of CfH₂⁺ carboxyl group is attracted by H-bond O1W—H11W···O3A with the water molecule, which simultaneously forms H-bond O1W—H11W···O3A with Hba⁻. This is a 2-nodal net with stoichiometry (2-c)₂(4-c) and point symbol (6.10⁵)(6)₂, which is also new [32]. There are two most interesting motifs in this network: R₂²(8) and R₁₀⁹(52) (Fig. 3c). Also, there are π - π interactions between the two rings of CfH₂⁺ (Table 2S, Fig. 4S).

It is possible to point out the similarity in the structure of the compounds under study. Water molecules stabilize crystal structures **1-3** by forming a diverse arrangement of supramolecular heterosynthons (Fig. 3). There are two intramolecular hydrogen bonds C—H···F, O—H···O in **1-3** (Fig. 2). The carbonyl and carboxyl groups of CfH₂⁺ are involved in a strong intramolecular O3—H···O1 hydrogen bond and, therefore, the O3—H group does not participate in the formation of intermolecular hydrogen bonds. This limits the possibility of fluoroquinolones self-association, for example, in **1-3**, CfH₂⁺ cations are not directly related to each other. In **2** and **3**, the CfH₂⁺ ions are bound to Hba or H₂ba by hydrogen bond N1—H...O (Table 2), but in **1**, CfH₂⁺ ions are bound to Htba⁻ through bridging water molecules. Compounds **1-3** possess very similar bond lengths O—C, C4—C5, and C5—C6 in the O=C₄—C₅H—C₆=O group (Fig. 2, Table 1S), and that indicates the formation of the Hba⁻ and Htba⁻ anions accompanied by the charge delocalization. Earlier, such delocalization was observed in other 2-thiobarbiturates [23-31] and 1,3-diethyl-2-thiobarbiturates [39-43]. Structures **1-3** are stabilized by π – π interactions between CfH₂⁺ ions of the head-to-tail type. These interactions connect CfH₂⁺ ions in pairs in structures **1-3** (Table 2S, Fig. 4S). Also, there are π - π interactions between Htba⁻/Hba⁻ and CfH₂⁺ ions in **1-2**.

3.3. Theoretical consideration

It is generally accepted that the reaction of an acid (in our case H_2 tba and H_2 ba) with a base (CfH) is expected to form a salt if $\Delta p K_a = p K_a$ (base) $- p K_a$ (acid) > 2 or 3 [44]. In spite of that the $p K_a$ value describes equilibrium phenomena in the solution, it remains to be a useful method for the prediction of the ionization state in crystals [44].

```
\begin{split} & CfH_2{}^+ \leftrightarrow CfH + H^+ \quad pK_a{}= 6.05 \text{ [45]} \\ & H_2tba \leftrightarrow Htba^- + H^+ \quad pK_a{}= 1.87 \text{ [46]}, \\ & H_2ba \leftrightarrow Htba^- + H^+ \quad pK_a{}= 4.03 \text{ [47]} \\ & \\ & For \ reaction \ H_2tba + CfH \leftrightarrow Htba^- + CfH_2{}^+ \\ & K_{eq} = \text{ [Htba}^-] \text{ [CfH}_2{}^+]/ \text{ [H}_2tba] \text{ [CfH]} = 10^{6.05} / 10^{1.87} = 10^{4.18} \ \approx 1.51 \cdot 10^4. \end{split}
```

Therefore, the concentration of ionized species will be $1.51 \cdot 10^4$ times greater that the concentration of non-ionized species in an aqueous solution, containing the equimolar amounts of CfH and H₂tba. The salt formation of **1** is consistent with the ΔpK_a rule.

```
For reaction H_2ba + CfH \leftrightarrow Hba^- + CfH_2^+ K_{eq} = \text{ [Hba}^-\text{] [CfH}_2^+\text{]/ [H}_2ba\text{] [CfH]} = 10^{6.05} / 10^{4.03} = 10^{2.02} \approx 105.
```

In the aqueous solution, containing the equimolar amounts of CfH and H_2 ba, the ΔpK_a value for the interaction between CfH₂⁺ and H₂ba is 2.02 which is also preferable for the formation of salt 3. However, at molar ratio CfH: H_2 ba = 1:2 (pH 4), the ionized and non-ionized H_2 ba species are coexisted in approximately equal concentrations. Thus, a favorable condition appears for the crystallization of phase 2, containing H₂ba molecules and Hba⁻ anions together. The C—O distances (d(O1A—C2A) = 1.235(2) Å, d(O2A—C4A) = 1.265(2) Å, d(O3A—C6A) = 1.265(2)Å in the Hba⁻ ion (A) (Table 1S) are greater than the C—O distances in the un-ionized trioxo form of H₂ba [37]. The C—O distances (d(O1B—C2B) = 1.218(2) Å, d(O2B—C4B) = 1.230(2)Å, d(O3B-C6B) = 1.206(2) Å in the H₂ba (B) molecule coincide with the distances of C-O in the molecular trioxo form of H₂ba. A similar difference between the lengths of the C—O bonds in the Hba⁻ ion and the H₂ba molecule was found in other salt co-crystals. For example, d(O—C) of H_2 ba in salt co-crystals $Rb(Hba)(H_2ba)\cdot 3H_2O$ [17], $M(Hba)(H_2ba)\cdot 3H_2O$ (M = Na, K), $K(Hba)(H_2ba)_{0.5}\cdot 1.5H_2O$ [10], $MBr\cdot H_2ba$ (M =Rb, Cs) and $CsI\cdot H_2ba$ [38] are in the range of 1.21-1.22 Å, but these values of Hba are bigger and they are in the range of 1.23-1.27 Å. The distances O—C in the trioxo form of detached H₂ba (1.21–1.22 Å) [37] are similar to those in the above mentioned co-crystals and compounds $[Ca(\mu_3-H_2ba-O,O',O'')]X_2$ (X = Cl [12], I [48]).

The equilibrium equation for solubility 2 has the form:

$$CfH_2(Hba)(H_2ba)\cdot 3H_2O \leftrightarrow CfH_2^+ + Hba^- + H_2ba + 3H_2O$$

The concentration of water can be considered as almost constant and, at pH 4, ciprofloxacin exists almost completely in the form of a CfH₂⁺ cation [45]. Therefore, the minimal solubility of 2 corresponds to the maximal value of the product of equilibrium concentrations [Hba⁻]·[H₂ba] in the aqueous solution. It is easy to show that the minimal solubility should be observed under the condition of [Hba⁻] = [H₂ba] and at pH = pK_a \approx 4. Such equilibrium pH value was established immediately after the completion of crystallization 2 from the aqueous solution containing stoichiometric amounts of CfH·HCl·H₂O, H₂ba and NaOH (Section 2.2).

3.4 IR spectroscopy

In good agreement, FTIR patterns of 1-3 display the characteristic absorption bands of CfH and barbituric/thiobarbituric acid, showing their multicomponent crystalline composition (Fig. 5S). For all compounds, the resulting spectra are different from the superimposed spectra of the starting materials. These changes point out to a different set of extended hydrogen bonding interactions for the carbonyl, hydroxyl and amino groups present in the crystal structures. In the region of stretching vibrations $\nu(COOH)$, $\nu(C=O)$, $\nu(NH)$ and $\nu(NH^+)$, IR spectra contain a large number of bands which complicate their assignment [7]. Thus, the assignment of the IR vibrational bands to the corresponding normal modes is based on [49-51]. The very broad bands in the 3600-3400 cm⁻¹ region can be assigned to the stretching modes of NH and OH groups in CfH₂⁺, Htba⁻ and Hba⁻ ions. The absorption bands at 1709 cm⁻¹ for 1, 1679 cm⁻¹ for 2 and 1686 cm⁻¹ for 3 are attributed to the v (COOH) vibrations in the CfH₂⁺ cation [9, 51]. The NH group of the piperazine ring was protonated in the crystalline compounds, and it is represented by the occurrence of medium intensity bands in the 2400-2700 cm⁻¹ region [9]. These data suggest the salt formation by a proton transfer from the barbituric/thiobarbituric acid to CfH. In the IR spectra of H₂ba, the highest frequency band at 1752 cm⁻¹ is associated with the 4,6-CO symmetric vibration $v_s(C=0)$ [36, 50]. In the IR spectra of 2, it is observed at 1722 cm⁻¹, which agrees with the presence of the neutral H₂ba molecule, i.e. with the formation of a salt co-crystal. Therefore, infrared spectroscopy gave the evidence of the salt formation in 1, 3 and the salt cocrystal formation in 2.

3.5. Thermal decomposition

The thermal decomposition of **1** starts at ~55 °C by a loss of crystal water molecules, and it is accompanied by the endoeffect at 92.6 °C (Fig. 6S). The water removal is confirmed by the IR spectroscopic analysis of released gases. In the range from ~150 °C to ~270 °C, the sample mass is nearly persistent, and the mass lost (Δm) at 150 °C (9.2%) almost coincides with that calculated at the assumption of three water molecules release (10.2%). The average value of the CfH melting temperature is equal to 270.0 °C [52, 53], and H₂tba melts with the decomposition at 250.6 °C [54]. Thus, compound **1** is thermally more stable than H₂tba. The melting accompanied by the oxidation of **1** occurred at T>270 °C, and the mass of the sample decreased rapidly in accordance to the mean TG curve. These transformations are accompanied by the endoeffect at 288.2 °C and mild exo-effect above 325 °C. According to the IR spectroscopic analysis of the gases evolved during thermolysis, H₂O, CO₂, NH₃ and SO₂ are formed.

In **2**, the crystal water loss starts at ~50 °C and it is accompanied by the endoeffects at 70.2 °C and 101.3 °C (Fig. 7S). Over the range from ~150 °C to ~250 °C, the mass of the sample is practically unchanged, and the mass lost (Δ m) at 150 °C (7.6%) almost coincides with that calculated assuming the three water molecules release (8.4%). The sample **2** melting is accompanied by the oxidation occurred at T>250 °C, and the sample mass decreased rapidly at T>275 °C according to the mean TG curve. H₂ba melts with the decomposition at 245.0 °C [10], i.e. compound **2** is more thermally stable than H₂ba. The oxidative decomposition of anhydrous organic residue is accompanied by a weak endo effect at 288.2 °C, strong exo-effect at 331.3 °C and emission of gaseous CO₂, H₂O and NH₃.

Both TG and DSC curves of 3 indicated one-step dehydration which is accompanied by the endo effect at 100.7 °C (Fig. 8S). This is confirmed by the results of evolved gases IR spectroscopic analysis. The dehydration stage in the range of 70-130 °C showed the weight loss (Δm) equal to 2.9%, but this value is lower than the calculated weight loss estimated under the assumption of total dehydration ($-H_2O$, $\Delta m_{theor}=3.6\%$). The underestimated Δm values for dehydration 1-3 are probably related to the samples partial dehydration in the air. The dehydration of 3 is accompanied by the endoeffect at 100.7 °C. According to TG curves, the mass of sample 3 remains unchanged up to ~275 °C (Fig. 8S) and, then, it follows by oxidative decomposition with the gaseous H_2O , CO_2 , NH_3 emissions. Similarly to 2, compound 3 is more thermal stable than H_2 ba.

Thus, the TG-DSC data confirm that compounds **1-3** are hydrates and the water contents approximately correspond to the established chemical compositions.

4. Conclusions

CfH crystallization with 2-thiobarbituric and barbituric acids resulted in the isolation of a new salt co-crystal (2) and two salts (1,3). The salt co-crystal is obtained in the region where the concentrations of ionized and nonionized H₂ba species are close so that both species can crystallize out. There are two intramolecular hydrogen bonds C-H···F, O-H···O (Fig. 2) and numerous intermolecular hydrogen bonds N-H···O, O-H···O in the structures of 1-3 (Fig. 3, Table 2). The dominant hydrogen bonding is the N-H···O interaction, which leads to a centrosymmetric synthon $R_2^2(8)$ and the formation of Htba⁻ pairs in 1 and the infinite chains of Hba⁻ ions in 2-3. The ciprofloxacinium cation has six potentially strong hydrogen bond acceptors and only two strong hydrogen bond donors (N atom in NH₂⁺ and O atom in COOH) (Fig. 1). However, the carbonyl and carboxyl groups of CfH₂⁺ are involved in a strong intramolecular hydrogen bond O3—H···O1 and, consequently, the O3—H group does not form a strong intermolecular hydrogen bond. Therefore, similar to structures 1-3, the self-association of fluoroquinolones with participation of O3–H group seems unlikely in other compounds. Water molecules stabilize crystal structures 1-3 by forming a diverse arrangement of supramolecular heterosynthons. The self-association of Htba-/Hba- ions and the interaction of complementary Hba[−] and H₂ba also stabilize the crystal structures of **1-3** (Fig. 3). In the O=C₄−C₅H−C₆=O group of Hba⁻ and Htba⁻ anions, the charge delocalization is observed (Table 1S). Structures 1-3 are stabilized by $\pi - \pi$ interactions between CfH₂⁺ ions joining them in pairs (Table 2S, Figure 4S).

Supplementary data

The crystallographic data (excluding structure factors) for the structural analysis have been deposited with Cambridge Crystallographic Data Centre ((1) - CCDC 1544127; (2) - CCDC 1544128; (3) - CCDC 1544129). The information may be obtained free of charge from The Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (Fax: +44(1223)336-033, E-mail: deposit@ccdc.cam.ac.uk, or www: www.ccdc.cam.ac.uk).

Acknowledgements

The study was carried out within the public task of the Ministry of Education and Science of the Russian Federation to the Siberian Federal University (4.7666.2017/BP) in 2017-2019. The reported study was funded by RFBR according to research projects 16-52-48010 and 17-52-53031. Also, the work was supported by Act 211, Government of the Russian Federation, contract 02.A03.21.0011 and by the Ministry of Education and Science of the Russian Federation (4.1346.2017/PP). The X-ray data from single crystals were obtained with the use of the analytical equipment from the SB RAS Krasnoyarsk Center of collective use.

References

- [1] L. A. Mitscher, Chem. Rev. 2005, 105(2), 559.
- [2] L. L. Shen, L. A. Mitscher, P. N. Sharma, T. J. O'Donnel, D. W. T. Chu, C. S. Cooper, T. Rosen, A. G. Pernet, *Biochem.* 1989, 28, 3886.
- [3] C. S. Prabodh, J. Ankit, J. Sander. *Acta Pol. Pharm-Drug Des.* **2009**, *66*, 587.
- [4] J. S. Reddy, S. V. Ganesh, R. Nagalapalli, R. Dandela, K. A. Solomon, K. A. Kumar, N. R. Goud, A. J. Nangia, *Pharm. Sci.* **2011**, *100*, 3160.
- [5] L. Mafra, S. M. Santos, R. Siegel, I. Alves, F. A. Almeida Paz, D. Dudenko, H. W. Spiess, *Am. Chem. Soc.* **2012**, *134*, 71.
- [6] D. L. Ross, C. M. Riley, Int. J. Pharm. 1990, 63, 237.
- [7] I. Turel, Coord. Chem. Rev., 2002, 232, 27.
- [8] R. Chadha, P. Singh, S. Khullarand, S. K. Mandal, Cryst. Growth Des., 2016, 16(9), 4960.
- [9] K. J. Paluch, T. McCabe, H. Müller-Bunz, O. I. Corrigan, A. M. Healyand, L. Tajber, *Mol. Pharmaceutics*, **2013**, *10*(*10*), 3640.
- [10] M. R. Chierotti, K. Gaglioti, R. Gobetto. D. Braga, F. Grepioni, L. Maini, *CrystEngComm*. **2013**, *15*, 7598.
- [11] S. Cherukuvada, R. Kaur, T. N. G. Row, CrystEngComm., 2016. DOI: 10.1039/c6ce1835a
- [12] D. Braga, F. Grepioni, G. I. Lampronti, L. Maini, A. Turrina, *Cryst. Growth Des.*, **2011**, *11(12)*, 5621.
- [13] Ö. Almarsson, M. J. Zaworotko, Chem. Commun., 2004, 17, 1889.
- [14] G. P. Stahly, Cryst. Growth Des., 2009, 9, 4212.
- [15] E. N. Padeiskaya, *Prevention, Diagnosis, and Pharmacotherapy of Some Infectious Diseases*, Bioinform, Moscow, **2002** (in Russian).
- [16] K. T. Mahmudov, M. N. Kopylovich, A. M. Maharramov, M. M. Kurbanova, A. V. Gurbanov, A. J. L. Pombeiro, *Coord. Chem. Rev.*, **2014**, 265, 1.
- [17] M. Gryl, K. Stadnicka, *Acta Crystallogr. E*, **2011**, *67*, m571.
- [18] N. N. Golovnev, M. S. Molokeev, I. V. Sterkhova, I. I. Golovneva, *J. Struct. Chem.*, **2016**, *57*(*6*), 1266.
- [19] Cambridge Structural Database, Version 5.37, Univ. of Cambridge, Cambridge, UK, 2015.
- [20] G. M. Sheldrick, Acta Cryst. A, 2008, 64, 112.
- [21] PLATON A Multipurpose Crystallographic Tool. Utrecht University, Utrecht, The Netherlands, **2008**.
- [22] K. Brandenburg, M. Berndt, DIAMOND Visual Crystal Structure Information System CRYSTAL IMPACT, Postfach 1251, D-53002 Bonn
- [23] N. N. Golovnev, M. S. Molokeev, Russ. J. Inorg. Chem., 2013, 58(10), 1193.

- [24] N. N. Golovnev, M. S. Molokeev, I. V. Sterkhova, V. V. Atuchin, M. Y. Sidorenko, *J. Coord. Chem.*, **2016**, *69*(21), 3219.
- [25] N. N. Golovnev, M. S. Molokeev, and M. Y. Belash, J. Struct. Chem., 2013, 54(3), 566.
- [26] N. N. Golovnev, M. S. Molokeev, S. N. Vereshchagin, and V. V. Atuchin, J. *Coord. Chem.*, **2013**, *66*(23), 4119.
- [27]. N. Golovnev, M. Molokeev, Acta Cryst. C, 2013, 69(7), 704.
- [28] N. N. Golovnev, M. S. Molokeev, S. N. Vereshchagin, V. V. Atuchin, M. Y. Sidorenko, M. S. Dmitrushkov, *Polyhedron*, **2014**, *70*, 71.
- [29] N. N. Golovnev, M. S. Molokeev, Russ. J. Inorg. Chem., 2014, 59(2), 72.
- [30] N. N. Golovnev, M. S. Molokeev, Russ. J. Coord. Chem., 2014, 40(9), 648.
- [31] N. N. Golovnev, M. S. Molokeev, J. Struct. Chem., 2014, 55(1), 125.
- [32] V. A. Blatov; A. P. Shevchenko; D. M. Proserpio. Crystal Growth & Design., 2014, 14, 3576.
- [33] H. C. Garcia, R. Diniz, M. I. Yoshida, L. F. C. de Oliveira, CrystEngComm., 2009, 11, 881.
- [34] H. C. Garcia, R. Diniz, M. I. Yoshida, L. F. C. de Oliveira, J. Mol. Struct., 2010, 978, 79.
- [35] H. C. Garcia, M. T. C. Camposa, H. G. M. Edwards, L. F. C. de Oliveira, *Vib. Spectrosc.*, **2016**, 86, 134.
- [36] H. C. Garcia, F. B. de Almeida, R. Diniz, M. I. Yoshida, L. F. C. de Oliveira, *J. Coord. Chem.*, **2011**, *64*, 1125.
- [37] T. C. Lewis, D. A. Tocher, S. L. Price, Cryst. Growth Des., 2004, 4(5), 979.
- [38] D. Braga, F. Grepioni, L. Maini, S. Prosperi, R. Gobetto, M. R. Chierotti, *Chem. Comm.*, **2010**, *46*, 7715.
- [39] N. N. Golovnev, M. S. Molokeev, S. N. Vereshchagin, I. V. Sterkhova, V. V. Atuchin, *Polyhedron*, **2015**, *85*, 493.
- [40] M. S. Molokeev, N. N. Golovnev, S. N. Vereshchagin, V. V. Atuchin, *Polyhedron*, **2015**, 98, 113.
- [41] N. N. Golovnev, M. S. Molokeev, A. S. Samoilo, V. V. Atuchin, *J. Coord. Chem.*, **2016**, 69(6), 957.
- [42] N. N. Golovnev, M. S. Molokeev, M. A. Lutoshkin, *Russ. J. Inorg. Chem.*, **2015**, 60(5), 572.
- [43] N. N. Golovnev, M. S. Molokeev, I. I. Golovneva, *Russ. J. Coord. Chem.*, **2015**, 41(5), 300.
- [44] S. L. Childs, P. Stahly, A. Park, Mol. Pharmaceutics, 2007, 4(3), 323.
- [45] V. M. Nurchi, G. Crisponi, J. I. Lachowicz, M. A. Zoroddu, M. Peana, S. Medici, D. Veclani, M. Tolazzi, A. Melchior, *Eur. J. Pharm. Sci.*, **2016**, *93*, 381.

- [46] E. Mendez, M. F. Cerda, J. S. Gancheff, J. Torres, C. Kremer, J. Castiglioni, M. Kieninger, O. N. Ventura, *J. Phys. Chem. C*, **2007**, *111*(8), 3369.
- [47] D. Braga, M. Cadoni, F. Grepioni, L.Maini, K. Rubini, CrystEngComm., 2006, 8, 756.
- [48] D. Braga, F. Grepioni, L. Maini, G.I. Lampronti, D. Capucci and C. Cuocci, *CrystEngComm.*, **2012**, *14*, 3521.
- [49] N. A. Smorygo, B. A. Ivin, Khim. Geterotsikl. Soedin., 1975, 10, 1402.
- [50] J. T. Bojarski, J. L. Mokrosz, H. J. Barton, M. H. Paluchowska, *Adv. Heterocycl. Chem.*, **1985**, *38*, 229.
- [51] V. L. Dorofeev, Pharmaceutical Chemistry Journal, 2004, 38(12), 693.
- [52] G. P. Vitorino, N. R. Sperandeo, M. R. Caira, M. R. Mazzieri, *Cryst. Growth Des.*, **2013**, 13, 1050.
- [53] S. V. Blokhina, A. V. Sharapova, M. V. Ol'khovich, T. V. Volkova, G. L. Perlovich, *Eur. J. Pharm. Sci.*, **2016**, *93*, 29.
- [54] N. N. Golovnev, M. S. Molokeev, L. S. Tarasova, V. V. Atuchin, N. I. Vladimirova, *J. Mol. Struct.*, **2014**, *1068*, 216.

 Table 1. (1-3) crystal structure parameters

Single crystal	CfH ₂ (Htba)·3H ₂ O (1)	$CfH_2(Hba)(H_2ba)\cdot 3H_2O$ (2)	CfH ₂ (Hba)·H ₂ O (3)
Moiety formula	C ₂₁ H ₂₈ FN ₅ O ₈ S	$C_{21}H_{28}FN_5O_8S$ $C_{25}H_{32}FN_7O_{12}$	
Dimension (mm)	$0.15 \times 0.07 \times 0.02$	$0.25 \times 0.25 \times 0.12$	$0.30 \times 0.02 \times 0.02$
Color	Pale yellow	Pale yellow	Colourless
Molecular weight	529.54	641.57	477.45
Temperature (K)	150	150	293
Space group, Z	<i>P</i> -1, 2	<i>P</i> -1, 2	$P2_{1}/c, 4$
a (Å)	10.640 (2)	10.352 (2)	10.2756 (7)
b (Å)	10.710 (2)	10.789 (2)	18.843 (2)
c (Å)	11.476 (2) 13.440 (3)		12.049 (1)
α (°)	68.64 (3) 72.53 (3)		90
β (°)	78.31 (3)	82.41 (3)	113.364 (2)
γ (°)	84.37 (3)	78.73 (3)	90
$V(\mathring{\mathrm{A}}^3)$	1192.2 (5)	1399.8 (6)	2141.8 (3)
ρ_{calc} (g/cm ³)	1.475	1.522	1.481
$\mu (mm^{-1})$	0.201	0.127	0.118
Reflections measured	13762	15702	10930
Reflections independent	5464	6407	4378
Reflections with $F > 4\sigma(F)$	2920	4653	1950
$2\theta_{max}$ (°)	55.08	55.04	52.80
h, k, l - limits	$-13 \le h \le 13;$ $-13 \le k \le 13;$ $-9 \le l \le 14$	$-13 \le h \le 10;$ $-13 \le k \le 12;$ $-17 \le l \le 17$	$-10 \le h \le 12;$ $-23 \le k \le 19;$ $-15 \le l \le 15$
$R_{ m int}$	0.0773	0.033	0.065
The weighed refinement of	$w=1/[\sigma^2(F_0^2)+(0.0472)]$	$w=1/[\sigma^2(F_0^2)+(0.0573P)^2+$	$w=1/[\sigma^2(F_0^2)+(0.055)]$
F^2	$P)^2$]	0.2036 <i>P</i>]	$(7P)^2$
No. of refinement parameters	346	427	316
$R1 [F_o > 4\sigma(F_o)]$	0.0593	0.0433	0.0587
wR2	0.1052	0.1046	0.1068
Goof	0.949	1.013	0.932
$\Delta \rho_{max} \ (e/\mathring{A}^3)$	0.307	0.323	0.180
$\Delta \rho_{min}~(e/\mathring{A}^3)$	-0.340	-0.273	-0.243
$(\Delta/\sigma)_{ m max}$	0.001	0.002	0.000

Table 2. Hydrogen-bond geometry in (1-3) structures (Å, °).

D—H	d(D—H)	d(H···A)	∠ D—H····A	D···A	A	Transformation for A atom	
CfH ₂ (Htba)·3H ₂ O (1)							
O3—H3	0.90(3)	1.70 (3)	151 (3)	2.522 (4)	O1	x, y, z	
C1—H01A	0.97	2.16	128	2.861 (4)	F	x, y, z	
N1—H0A	0.89	2.01	156	2.843 (3)	O2W	1+x, y, z	
N1B—H1B	0.86	1.89	168	2.734 (4)	O2B	2-x, 1-y, 1-z	
N1—H0B	0.89	1.95	169	2.827 (3)	O1W	1-x, 1-y, 1-z	
N3B—H3B	0.86	2.42	168	3.270 (2)	S	1-x, 1-y, 1-z	
O1W—H11W	0.84(2)	2.09 (2)	169 (3)	2.918 (3)	O3W	1-x, 2-y, 1-z	
O1W—H12W	0.89 (3)	1.86 (3)	166 (3)	2.728 (3)	O2B	1+x, y, z	
O2W—H21W	0.91 (3)	1.91 (3)	156 (3)	2.762 (4)	O2	x, -1+y, z	
O2W—H22W	0.89 (3)	1.96 (3)	168 (3)	2.834 (3)	O3W	1-x, 1-y, 1-z	
O3W—H31W	0.85 (3)	2.03 (3)	156 (3)	2.829 (3)	O1B	1-x, 2-y, 1-z	
O3W—H32W	0.92(3)	1.84 (3)	171 (3)	2.756 (3)	O1B	x, y, z	
$CfH_2(Hba)(H_2ba)\cdot 3H_2O$ (2)							
O3—H3	0.87(2)	1.70 (2)	160 (2)	2.532 (2)	O1	x, y, z	
C1—H01B	0.97	2.22	125	2.894 (2)	F	x, y, z	
N1—H0A	0.89	1.84	172	2.727 (2)	O3A	1-x, 2-y, -z	
N1—H0B	0.89	1.95	168	2.832 (2)	O2B	1+x, 1+y, z	
N1A—H1A	0.86	2.10	169	2.947 (2)	O1B	x, y, z	
N1B—H1B	0.86	1.97	172	2.824 (2)	O1A	x, y, z	
N3A—H3A	0.86	2.00	175	2.860 (2)	O2B	1+x, y, z	
N3B—H3B	0.86	1.91	171	2.762 (2)	O2A	1-x, y, z	
O1W—H11W	0.87 (2)	1.90(2)	173 (2)	2.764 (2)	O2A	1-x, 1-y, -z	
O1W—H12W	0.92(2)	1.93 (2)	160 (2)	2.805 (2)	O2W	-x, 1-y, -z	
O2W—H21W	0.92(2)	1.84 (2)	164 (2)	2.741 (2)	O1W	x, 1+y, z	
O2W—H22W	0.87 (2)	1.87 (2)	171 (2)	2.762 (2)	O3A	x, y, z	
O3W—H31W	0.90(2)	2.13 (2)	153 (2)	2.965 (2)	O2	1-x, -y, 1-z	
O3W—H32W	0.94(2)	2.08 (2)	169 (2)	3.004 (2)	O1	x, y, z	
CfH ₂ (Hba)·H ₂ O (3)							
O2—H2	0.92 (3)	1.63 (4)	156 (3)	2.502 (4)	O1	x, y, z	
C1—H01A	0.97	2.25	124	2.902 (4)	F	x, y, z	
N1—H0A	0.89	1.83	168	2.708 (3)	O2A	x, y, z	

N1A—H1A	0.86	2.09	163	2.924 (3)	O1A	1-x, 2-y, 1-z
N1B—H1B	0.86	1.98	173	2.831 (3)	O2A	-x, 2-y, 1-z
O1W—H11W	0.94 (3)	1.84 (3)	174 (3)	2.779 (4)	O3A	x, y, z
O1W—H12W	0.92 (4)	1.94 (4)	173 (3)	2.859 (4)	O2W	-x, 1-y, 1-z




Figure 1. Schemes of ciprofloxacin (a) and barbituric acids (b): X=O in H₂ba and X=S in H₂tba.




Fig. 2 The asymmetric part of the unit cell: a) CfH₂(Htba)·3H₂O (1); b) CfH₂(Hba)(H₂ba)·3H₂O (2); c) CfH₂(Hba)·H₂O (3). Ellipsoids are drawn at the 50% probability level, except for the hydrogen atoms represented by spheres. The intramolecular hydrogen bonds are shown with dashed lines.




Fig. 3 Hydrogen bonding in **1** (a), **2** (b) and **3** (c). The H-bonds are marked by dashed lines, the H-bond motifs are marked by circles and broad lines. Labels A and B in **2** marked Hba $^-$ and H₂ba, respectively.